Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
DehydraTECH TM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing KELOWNA, BC / ACCESSWIRE / March 24, 2021 / Lexaria ...
(TheNewswire) Lexaria recently announced progress on its hypertension R&D program, consisting of three human clinical and two animal studies, as well as two studies in its antiviral drug evaluation program Kelowna, British Columbia &...
(TheNewswire) - Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 Kelowna, British Columbia - TheNewswire - March 16, 2021 – Lexaria Bioscien...
Five studies underway to examine DehydraTECH TM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress i...
Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Comp...
(TheNewswire) Kelowna, British Columbia – TheNewswire - February 16, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”),...
Hypertension program evaluating effectiveness of DehydraTECH-processed CBD now consists of three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / February 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), ...
KELOWNA, BC / ACCESSWIRE / February 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces applied R&D programs to begin immediately. Lexaria recently closed an oversubscribed finan...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors. Mr. Reese has over...
KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common st...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...